ATE489966T1 - Verbundsuperimmunogen zur verwendung als bifunktioneller impfstoff (tat-gp160) zur behandlung von aids - Google Patents
Verbundsuperimmunogen zur verwendung als bifunktioneller impfstoff (tat-gp160) zur behandlung von aidsInfo
- Publication number
- ATE489966T1 ATE489966T1 AT02772502T AT02772502T ATE489966T1 AT E489966 T1 ATE489966 T1 AT E489966T1 AT 02772502 T AT02772502 T AT 02772502T AT 02772502 T AT02772502 T AT 02772502T AT E489966 T1 ATE489966 T1 AT E489966T1
- Authority
- AT
- Austria
- Prior art keywords
- superimmunogen
- tat
- aids
- compound
- treatment
- Prior art date
Links
- 230000001588 bifunctional effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000030507 AIDS Diseases 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000001364 causal effect Effects 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 231100000110 immunotoxic Toxicity 0.000 abstract 1
- 230000002625 immunotoxic effect Effects 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001134—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001135—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0110751A FR2828404B1 (fr) | 2001-08-10 | 2001-08-10 | Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal |
| PCT/FR2002/002853 WO2003013593A2 (fr) | 2001-08-10 | 2002-08-09 | Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE489966T1 true ATE489966T1 (de) | 2010-12-15 |
Family
ID=8866487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02772502T ATE489966T1 (de) | 2001-08-10 | 2002-08-09 | Verbundsuperimmunogen zur verwendung als bifunktioneller impfstoff (tat-gp160) zur behandlung von aids |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20040185058A1 (de) |
| EP (1) | EP1427441B1 (de) |
| JP (1) | JP2005502647A (de) |
| CN (1) | CN1568197A (de) |
| AT (1) | ATE489966T1 (de) |
| AU (1) | AU2002337268B2 (de) |
| CA (1) | CA2456802A1 (de) |
| DE (1) | DE60238492D1 (de) |
| DK (1) | DK1427441T3 (de) |
| ES (1) | ES2355711T3 (de) |
| FR (1) | FR2828404B1 (de) |
| WO (1) | WO2003013593A2 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE500848T1 (de) * | 2005-05-24 | 2011-03-15 | Neovacs | Verfahren zur herstellung eines stabilen immunogenen produkts beinhaltend antigene- heterokomplexe aus tnf-aplha und einem trägerprotein |
| PE20110023A1 (es) | 2009-06-22 | 2011-01-31 | Wyeth Llc | Composiciones inmunogenicas de antigenos de staphylococcus aureus |
| EP3461496B1 (de) | 2009-06-22 | 2023-08-23 | Wyeth LLC | Zusammensetzungen und verfahren zur herstellung von staphylococcus aureus serotyp-5 und 8-kapselpolysaccharid-konjugat-immunogenzusammensetzungen |
| CN105327350A (zh) * | 2014-07-23 | 2016-02-17 | 中国科学院上海巴斯德研究所 | 泛素化途径相关因子在调控辅助性t细胞功能中的应用 |
| WO2024121424A1 (en) | 2022-12-09 | 2024-06-13 | Daniel Zagury | Composite aids vaccine generating anti-hiv specific neutralizing antibodies and/or anti-hiv cytotoxic t cells |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2677654B1 (fr) * | 1991-06-17 | 1995-11-17 | Pasteur Merieux Serums Vacc | Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv. |
| AU4727296A (en) * | 1995-02-24 | 1996-09-11 | Cantab Pharmaceuticals Research Limited | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
| BR9607659A (pt) * | 1995-03-08 | 1998-12-15 | Neovacs | Composto imunogênio composição processos para preparação de um composto imunogênico de um anticorpo anti-proteína e de um fragmento anticorpo anti-proteína e fragmento |
| US5965532A (en) * | 1996-06-28 | 1999-10-12 | Trustees Of Tufts College | Multivalent compounds for crosslinking receptors and uses thereof |
| FR2773156B1 (fr) * | 1997-12-26 | 2000-03-31 | Biovacs Inc | Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida |
| FR2781158B1 (fr) * | 1998-07-15 | 2002-12-13 | Vacs Internat | Nouvelles proteines modifiees immunogenes non immunosuppressives, leur procede de preparation et leurs applications |
| WO2000023955A1 (en) * | 1998-10-21 | 2000-04-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Virus-like particles for the induction of autoantibodies |
| AU5617900A (en) * | 1999-06-17 | 2001-01-09 | Robert C. Gallo | Chimeric chemokine-antigen polypeptides and uses therefor |
| FR2802426B1 (fr) * | 1999-12-15 | 2004-04-02 | Neovacs | Utilisation de proteines immunogenes immunosuppressives et/ou angiogeniques rendues inactives, pour la production d'iga secretoires |
| JP2003529559A (ja) * | 2000-01-31 | 2003-10-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規用途 |
| FR2812813B1 (fr) * | 2000-08-09 | 2004-11-26 | Neovacs | Utilisation d'immunogenes pour traiter ou prevenir au sein des tumeurs malignes les dereglements immunitaires induits par des facteurs extracellulaires |
-
2001
- 2001-08-10 FR FR0110751A patent/FR2828404B1/fr not_active Expired - Fee Related
-
2002
- 2002-08-09 CN CNA028200845A patent/CN1568197A/zh active Pending
- 2002-08-09 DK DK02772502.7T patent/DK1427441T3/da active
- 2002-08-09 EP EP02772502A patent/EP1427441B1/de not_active Expired - Lifetime
- 2002-08-09 WO PCT/FR2002/002853 patent/WO2003013593A2/fr active Application Filing
- 2002-08-09 DE DE60238492T patent/DE60238492D1/de not_active Expired - Lifetime
- 2002-08-09 ES ES02772502T patent/ES2355711T3/es not_active Expired - Lifetime
- 2002-08-09 US US10/486,329 patent/US20040185058A1/en not_active Abandoned
- 2002-08-09 AT AT02772502T patent/ATE489966T1/de active
- 2002-08-09 JP JP2003518597A patent/JP2005502647A/ja active Pending
- 2002-08-09 CA CA002456802A patent/CA2456802A1/fr not_active Abandoned
- 2002-08-09 AU AU2002337268A patent/AU2002337268B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE60238492D1 (de) | 2011-01-13 |
| ES2355711T3 (es) | 2011-03-30 |
| CA2456802A1 (fr) | 2003-02-20 |
| US20040185058A1 (en) | 2004-09-23 |
| WO2003013593A3 (fr) | 2003-10-02 |
| FR2828404A1 (fr) | 2003-02-14 |
| AU2002337268B2 (en) | 2007-02-01 |
| EP1427441A2 (de) | 2004-06-16 |
| CN1568197A (zh) | 2005-01-19 |
| JP2005502647A (ja) | 2005-01-27 |
| FR2828404B1 (fr) | 2005-07-15 |
| WO2003013593A2 (fr) | 2003-02-20 |
| DK1427441T3 (da) | 2011-02-28 |
| EP1427441B1 (de) | 2010-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE426412T1 (de) | Adjuvante influenza-vakzine | |
| ATE542829T1 (de) | Impfstoff | |
| WO2004060308A3 (en) | Thiosemicarbazones as anti-virals and immunopotentiators | |
| ATE396739T1 (de) | Entwicklung einer vakzine zur prävention von infektionen mit filovirus bei primaten | |
| AU2001235006A1 (en) | Prophylactic and therapeutic monoclonal antibodies | |
| TNSN07150A1 (en) | Semi-soft c-class immunostimulatory oligonucleotides | |
| ATE267830T1 (de) | Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen | |
| NO20050091L (no) | Fremgangsmater for fremstilling av fibrinogen | |
| EA201000903A1 (ru) | Антитела к pcrv-антигену pseudomonas aeruginosa | |
| PT1409692E (pt) | Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina | |
| MA32388B1 (fr) | Immunomodulation par des inhibiteurs d'iap | |
| ATE312096T1 (de) | Neue verbindungen | |
| EA200601217A1 (ru) | Новые конденсированные пирролокарбазолы | |
| ATE458496T1 (de) | Hiv-vakzine und anwendungsverfahren | |
| MXPA03000279A (es) | Uso de cepas del parapoxvirus ovis para la fabricacion de medicamentos antivirales y medicamentos contra el cancer. | |
| WO2006024240A3 (es) | Composición vacunal contra el virus de la hepatitis c. | |
| ATE489966T1 (de) | Verbundsuperimmunogen zur verwendung als bifunktioneller impfstoff (tat-gp160) zur behandlung von aids | |
| YU68602A (sh) | Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje | |
| MX2009005026A (es) | Anticuerpos anti-tsg101 y sus usos para tratamiento de infecciones virales. | |
| ES2502366T3 (es) | Inducción de inmunidad tumoral por variantes de proteína de unión a folato | |
| WO2007076091A3 (en) | Treatment of viral infections using a tissue factor inhibitor | |
| SG147465A1 (en) | Vaccine | |
| DK1740206T3 (da) | PHEP, en aminosyrepermease af Staphylococcus Aureus | |
| WO2020053742A3 (en) | Anti-hla-hbv peptide antibodies | |
| WO2003070159A3 (en) | Novel coumarin and chromene compounds and methods of treating or preventing viral infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1427441 Country of ref document: EP |